
ã³ãããæ³šå°ãè³åäžãå¿èçºäœãå åèçŸæ£ãäžæŽèã®å€§å¹ å¢å ãšé¢é£ã8500äžäººã察象ãšããæ°ããªç ç©¶ã§å€æ
å èšäºã¯ãã¡ããã/Click here to read the original article.
2023幎3æã«**ãåœéäºé²å»åŠãžã£ãŒãã«ãã«çºè¡šãããç ç©¶ã§ã¯ãä»ã®ç ç©¶ã®çµæãåæããåèš8500äžäººã®ããŒã¿ãè©äŸ¡ããŸããããã®ç ç©¶ã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®ãšä»¥äžã®ããŸããŸãªå¥åº·ç¶æ ã®å¢å ãšã®é¢é£ã瀺ããŸãã: è³åäžïŒ+240%ïŒãå¿èçºäœïŒ+286%ïŒãå åèçŸæ£ïŒ+244%ïŒãããã³äžæŽèïŒ+199%ïŒ**ã
ãã®ç ç©¶ã¯ãCOVID-19ã¯ã¯ãã³ã®æå®³åœ±é¿ã«é¢ããå¢ãç¶ãã蚌æ ãããã«è£åŒ·ãããã®ãšãªã£ãŠããŸãã
2025幎3æ14æ¥ã«**ãåœéäºé²å»åŠãžã£ãŒãã«ã**ã«çºè¡šããããCOVID-19ã¯ã¯ãã³æ¥çš®ãšå¿è¡ç®¡ã€ãã³ãïŒäºé²çå©çãšãªã¹ã¯ã®ãã€ãºå€å€éã¡ã¿ã¢ããªã·ã¹ããšé¡ãããç ç©¶ã§ã¯ãCOVID-19ã¯ã¯ãã³ãšå¿è¡ç®¡çŸæ£ã®é¢é£æ§ã«ã€ããŠã®æ¢åã®æç®ãåæããã¯ã¯ãã³æ¥çš®ãšå¿è¡ç®¡ã®åé¡ãšã®é¢ä¿ãæããã«ããããšãç®çãšããŠããŸãã
ãã®ç ç©¶ã§ã¯ãããããŸã§ã«äžçäžã§118åå以äžã®ã¯ã¯ãã³æ¥çš®ãè¡ãããŠããããCOVID-19ã¯ã¯ãã³æ¥çš®ã«é¢é£ããå¥åº·ãªã¹ã¯ã«ã€ããŠã®æžå¿µãé«ãŸã£ãŠããããšã«èšåãããŠããŸãã
以åã®ç³»çµ±çã¬ãã¥ãŒãã¡ã¿ã¢ããªã·ã¹ã¯äž»ã«å¿ççãå¿èçãšãã£ãåé¡ã«çŠç¹ãåœãŠãŠãããCOVID-19ã¯ã¯ãã³æ¥çš®ãšä»ã®å¿è¡ç®¡ç³»ã®å䜵çãšã®é¢é£ã«ã€ããŠã¯ååã«æ¢æ±ãããŠããŸããã§ããããã®ãããèè ãã¯ãæ¬ç ç©¶ã®ç®çã¯ãã¯ã¯ãã³ã«é¢é£ããå¿è¡ç®¡ã€ãã³ãã®é¢é£æ§ã調ã¹ãããã«ã匷åãªãã€ãºå€å€éã¡ã¿ã¢ããªã·ã¹ã¢ãã«ãææ¡ããããšã§ãããšè¿°ã¹ãŠããŸãã
ãã€ãºå€å€éã¡ã¿ã¢ããªã·ã¹ã¯ãè€æ°ã®ç ç©¶ããã®èšŒæ ãçµã¿åãããŠãè€æ°ã®ã°ã«ãŒãéã§åäžã®çµæã«åºã¥ãæ¯èŒãè¡ãçµ±èšçæ¹æ³ã§ãããã®æ¹æ³ã¯ãããŒã¿ãšã¢ãã«ã®ãã©ã¡ãŒã¿ãã©ã³ãã 倿°ãšããŠæ±ããã¡ã¿ã¢ããªã·ã¹ãèšç®ããéã«äºåç¥èãä»®å®ãçµ±åããããšãã§ããŸãã
ç ç©¶è ãã¡ã¯ãPubMedãWeb of ScienceãScopusãCochrane LibraryãGoogle Scholarãªã©ã®äž»èŠãªé»åããŒã¿ããŒã¹ã䜿çšãã2023幎10æ22æ¥ãŸã§ã«COVID-19ã¯ã¯ãã³æ¥çš®ãšå¿è¡ç®¡ã€ãã³ãã«é¢ããé¢é£æç®ããã¹ãŠåéããŸããã
圌ãã¯ã人éã察象ãšããç ç©¶ã§ãç¹ã«COVIDã¯ã¯ãã³æ¥çš®åŸã®å¿è¡ç®¡ã€ãã³ãã«é¢ããå¯äœçšã«çŠç¹ãåœãŠãç ç©¶ãå«ãããã©ãã£ãã¬ãã¥ãŒã系統çã¬ãã¥ãŒãçäŸå ±åãããŒã¿ãäžååãªãªãªãžãã«è«æãè±èªä»¥å€ã®èšèªã§æžãããèšäºãé€å€ããŸãããå«ãŸããèšäºã®è³ªã¯ã2人ã®ã¬ãã¥ã¢ãŒã«ãã£ãŠç¬ç«ã«è©äŸ¡ãããŸããã
ç ç©¶è ãã¡ã¯1,266ä»¶ã®é¢é£ããèšäºãç¹å®ããè©³çŽ°ã«æ€èšããçµæãæçµçã«15ã®ç ç©¶ãæ®ãã11ä»¶ã®å¯Ÿç §çŸ€ãæã€ç ç©¶ãäž»åæã«éžã°ãã4ä»¶ã®å¯Ÿç §çŸ€ãæããªãç ç©¶ãäºæ¬¡åæã«å«ãŸããŸããã
éžã°ããç ç©¶ã§ã¯ããã¡ã€ã¶ãŒã®BNT162b2ã¯ã¯ãã³ãã¢ã¹ãã©ãŒãã«ã®ChAdOx1ã¯ã¯ãã³ãããã³ãã®ä»ã®ã¯ã¯ãã³ãæ¥çš®ããåèš3,777äžäººãååæ¥çš®ã807äžäººã2åç®æ¥çš®ã199,000人ã3åç®æ¥çš®ãåããŸããã
äž»åæã®çµæã¯ãå¿è¡ç®¡ã€ãã³ãã®ãªã¹ã¯ãCOVIDã¯ã¯ãã³ã®çš®é¡ãæ¥çš®åæ°ã«ãã£ãŠç°ãªãããšã瀺ããŸãããå ·äœçã«ã¯ãBNT162b2ã¯ã¯ãã³ã¯å åèçŸæ£ïŒCADïŒãå¿çæ¢å¡ãè³åäžã®ãªã¹ã¯ãå¢å ãããChAdOx1ã¯ã¯ãã³ã¯äžæŽèã®ãªã¹ã¯ãå¢å ãããããšã瀺ãããŸããããŸããCOVIDã¯ã¯ãã³ã®2åç®æ¥çš®ã¯å¿çæ¢å¡ãšCADã®ãªã¹ã¯ãé«ãã3åç®æ¥çš®ã¯å¿çæ¢å¡ã«ã¯åœ±é¿ãäžãããè³åäžã®ãªã¹ã¯ãæžå°ãããŸããã
åæã§ã¯ãã¢ãžã¢è«žåœã«ãããå åèçŸæ£ã®ã±ãŒã¹ãé€ããå°ççãªå°åã«åºã¥ãææãªçµæã¯åŸããããCOVIDã¯ã¯ãã³æ¥çš®ã«é¢é£ããå¿è¡ç®¡ã€ãã³ãã®ãªã¹ã¯ã¯å°ççèŠå ã«å€§ãã圱é¿ãããªãããšã瀺åãããŸããã
äºæ¬¡åæã§ã¯ãã¢ã¡ãªã«ã§è¡ããã6ã€ã®ç¬ç«ããç ç©¶ã®çµæãçµ±åããBNT162b2ã¯ã¯ãã³ãšã¢ãã«ãã®mRNA-1273ã¯ã¯ãã³ã®æ¯èŒãè¡ãããŸããããã®åæã§ã¯ãå¿è¡ç®¡ãžã®åœ±é¿ã«ã€ããŠäž¡ã¯ã¯ãã³ã®éã«ææãªå·®ã¯èŠããããäž¡æ¹ã®mRNAã¯ã¯ãã³ãå¿è¡ç®¡å¥åº·ã«äŒŒã圱é¿ãäžããããšã瀺ãããŸããã
ãã®ç ç©¶ã¯ãCOVID-19ã¯ã¯ãã³ãšå¿è¡ç®¡çŸæ£ãšã®é¢é£ãæç¢ºã«ç€ºãéèŠãªè¿œå ç蚌æ ãšãªããŸãã
èè ãã¡ã¯çµè«ãšããŠæ¬¡ã®ããã«è¿°ã¹ãŠããŸãïŒãæ¬ç ç©¶ã®çµæã¯ãä»åŸã®ãã³ãããã¯ã«å¯Ÿããå ¬è¡è¡çæ¿çã«åœ¹ç«ã€å¯èœæ§ããããCOVID-19ã¯ã¯ãã³æ¥çš®ã®æèã§å åèçŸæ£ïŒCADïŒãèæ ®ããã¯ã¯ãã³ãæäººã«æäŸããåã«å¿èã®ç¶æ ãè©äŸ¡ããããšãéèŠã§ãããã®ãããªãªã¹ã¯ãæå°éã«æããããã«ã¯ãæ°ããã¯ã¯ãã³ã®å¿è¡ç®¡å®å šæ§ãè©äŸ¡ããããã®å æ¬çãªåèšåºããã³èšåºç ç©¶ãè¡ãããã¹ãã§ããã倿§ãªäººå£ã察象ãšããå€§èŠæš¡ãªè©Šéšãå«ãã¹ãã§ããã
ãã®ç ç©¶ã®è©³çްãªçµæã«ãããŠãã¯ã¯ãã³æ¥çš®ã«é¢é£ããçã®ææãæããã«ãããŠããŸããç ç©¶ã®ææãšè³ªã®è©äŸ¡çµæã¯ãè«æã®è£è¶³è¡šã«è©³çްã«ç€ºãããŠããŸããActivist Postã«æ²èŒãããèšäºã§ãç«åŠè ã®ãã³ã©ã¹ã»ãã«ã·ã£ãŒæ°ã¯ããããã®è¡šã瀺ãå 容ãèŠçŽããŠããŸãã
COVID-19ã¯ã¯ãã³æ¥çš®åŸã®ãªã¹ã¯å¢å
ïŒæªæ¥çš®ïŒå¯Ÿç §çŸ€ãšæ¯èŒïŒ
å åèçŸæ£ (CAD):
å šäœ: OR 1.70 (95% CrI: 1.11â2.57) â 70% ã®ãªã¹ã¯å¢å
BNT162b2 (ãã¡ã€ã¶ãŒ): OR 1.64 (95% CrI: 1.06â2.55) â 64% ã®ãªã¹ã¯å¢å
2åç®æ¥çš®ïŒãã¹ãŠã®ã¯ã¯ãã³ïŒ: OR 3.44 (95% CrI: 1.99â5.98) â 244% ã®ãªã¹ã¯å¢å
å¿çæ¢å¡ (MI):
2åç®æ¥çš®ïŒãã¹ãŠã®ã¯ã¯ãã³ïŒ: OR 3.86 (95% CrI: 2.28â6.60) â 286% ã®ãªã¹ã¯å¢å
BNT162b2 (ãã¡ã€ã¶ãŒ): OR 1.87 (95% CrI: 1.22â2.89) â 87% ã®ãªã¹ã¯å¢å
BNT162b2 2åç®æ¥çš®: OR 3.84 (95% CrI: 2.21â6.66) â 284% ã®ãªã¹ã¯å¢å
è³åäž:
BNT162b2 (ãã¡ã€ã¶ãŒ): OR 2.09 (95% CrI: 1.36â3.21) â 109% ã®ãªã¹ã¯å¢å
BNT162b2 1åç®æ¥çš®: OR 3.69 (95% CrI: 2.13â6.37) â 269% ã®ãªã¹ã¯å¢å
1åç®æ¥çš®ïŒãã¹ãŠã®ã¯ã¯ãã³ïŒ: OR 3.40 (95% CrI: 1.98â5.86) â 240% ã®ãªã¹ã¯å¢å
äžæŽè:
1åç®æ¥çš®ïŒãã¹ãŠã®ã¯ã¯ãã³ïŒ: OR 2.99 (95% CrI: 1.20â7.44) â 199% ã®ãªã¹ã¯å¢å
ChAdOx1ïŒã¢ã¹ãã©ãŒãã«ïŒ: OR 8.11 (95% CrI: 3.67â17.99) â 711% ã®ãªã¹ã¯å¢å
ChAdOx1 1åç®æ¥çš®: OR 4.89 (95% CrI: 1.21â19.38) â 389% ã®ãªã¹ã¯å¢å
ãã®85äžäººãè¶ ããå€§èŠæš¡åæã¯ãCOVID-19ã¯ã¯ãã³ãè³åäžãå¿çæ¢å¡ãå åèçŸæ£ãäžæŽèã®ãªã¹ã¯ãå€§å¹ ã«å¢å ãããããšã瀺ããŠããŸããç¹ã«ããã¡ã€ã¶ãŒã®mRNAã¯ã¯ãã³ïŒBNT162b2ïŒã¯ãååããã³2åç®ã®æ¥çš®åŸã«è³åäžãå¿çæ¢å¡ãå åèçŸæ£ãšã®é¢é£ã匷ãèŠãããŸãããäžæŽèã®ãªã¹ã¯ã¯ãã©ã®ã¯ã¯ãã³ã®1åç®æ¥çš®åŸã§ãå¢å ããã¢ã¹ãã©ãŒãã«ã®ChAdOx1ã¯ã¯ãã³ã§ã¯æã匷ãä¿¡å·ãèŠãããŸããã
æ¥ã ãæ°ããç ç©¶ãå ¬éãããCOVID-19ã¯ã¯ãã³ãããããæ·±å»ãªå®³ãæããã«ãªã£ãŠããŸãããããã®ã¯ã¯ãã³ã¯å³åº§ã«åžå Žããæ€åãããã¹ãã§ãã
85äžäººèŠæš¡ã®ç ç©¶çµæã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã«è³åäžãå¿çæ¢å¡ãå åèçŸæ£ãäžæŽèã®ãªã¹ã¯å¢å ã確èªãããããšã瀺ããŠããŸããïŒActivist Post, 2025幎5æ6æ¥ïŒ
ãã«ã·ã£ãŒæ°ã¯ãäžèšã®ç ç©¶ãCOVID-19 mRNAã¯ã¯ãã³ã人éã«å¯ŸããŠå®å šã§ãªãããšã瀺ã4ã€ã®éèŠãªç ç©¶ã®ãã¡ã®1ã€ã§ãããšTwitterã§ææããŸããã
184 Million People, 4 Landmark Studies: COVID-19 mRNA Shots Are NOT SAFE FOR HUMAN USE ð«
â Nicolas Hulscher, MPH (@NicHulscher) April 13, 2025
𩞠Autopsies. Heart Attacks. Strokes. Multi-Organ Failure â The Data Are In ð
ðFAKSOVA ET AL (n=99 million):
â Myocarditis (+510% after mRNA injection)
â Acute Disseminated⊠pic.twitter.com/Rmgzo8cmvm
ãã«ã·ã£ãŒæ°ã¯ãŸããå æMITã®ã¬ãã»ãã»ã¬ãŽã£ææãšãããªãå·ã®ãžã§ã»ãã»ã©ããå€ç§å»ãäž»å°ããç ç©¶ããã®çµæãåºã«æšèšãããã¡ã€ã¶ãŒã®COVID-19ã¯ã¯ãã³ã ãã§ã¢ã¡ãªã«ã§æ»äº¡ãã人æ°ã¯47äžäººã«äžããšå ±åããŠããŸãã
ãéèŠãªã®ã¯ããã®æšèšã¯ãããäžã€ã®éåžžã«å±éºãªmRNAã¯ã¯ãã³ïŒã¢ãã«ãïŒãšã®æ¯èŒã«åºã¥ããŠããŸãããããã£ãŠã47äžäººãšããã¢ã¡ãªã«ã®æ»äº¡è æ°ã®æšèšã¯éåžžã«ä¿å®çã§ãããå®éã®æ»äº¡çã®å¢å ã¯æªæ¥çš®ãšæ¯èŒããŠãã£ãšé«ãå¯èœæ§ããããšããããšã§ãããšãã«ã·ã£ãŒæ°ã¯è¿°ã¹ãŠããŸãã
ããã«ããããã¯ãVAERSïŒã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒããã®60äžäººä»¥äžã®ã¢ã¡ãªã«ã®COVID-19ã¯ã¯ãã³ã«ããæ»äº¡è æ°ã®æšèšããéåžžã«çŸå®çã§ãããä¿å®çãªæšèšã§ãããããšãæå³ããŠããŸãããšä»ãå ããŸããã
ãèŽåœçãªCOVID-19 mRNAã¯ã¯ãã³ã¯ãä»ã§ãäœçŸäžäººãã®ã¢ã¡ãªã«ã®åäŸãã¡ã«æ¥çš®ãããŠãããç¬¬äžæ¬¡äžç倧æŠãç¬¬äºæ¬¡äžç倧æŠããããã æŠäºãåããããããå€ãã®ã¢ã¡ãªã«äººã®åœã奪ã£ãŠããŸãããšåœŒã¯è¿°ã¹ãŸããã